Neumora Therapeutics (NMRA) announced results from the Phase 3 KOASTAL-1 Study of navacaprant for the treatment of major depressive disorder. The KOASTAL-1 Study is the first of three replicate ...
Navacaprant is an highly selective kappa opioid receptor antagonist expected to modulate reward processing pathways and mediate depressive states.
Neumora Therapeutics' lead candidate, navacaprant, failed to meet primary and secondary endpoints in its Phase 3 KOASTAL-1 ...
Massachusetts, USA-based based brain disease biotech Neumora Therapeutics shares tumbled 81.4% to 1.97 after it revealed that ...
The KOASTAL-1 study enrolled 383 adult patients with MDD. Navacaprant was shown to be safe and generally well-tolerated with ...
The well-funded biotech lost most of its value after its drug flunked a late-stage trial. One analyst described the results ...
Medpage Today on MSN1d
6% of Seniors Depressed; ADHD and Hormones; Novel Antipsychotic Eases SchizophreniaA study of older adults showed that 6% had depression, with higher prevalences in certain groups, including women, those who ...
Neumora Therapeutics’ phase 3 KOASTAL-1 study of navacaprant in MDD fails to meet primary endpoint
Watertown, Massachusetts Friday, January 3, 2025, 18:00 Hrs [IST] ...
In a highly anticipated readout for the kappa opioid receptor class in major depressive disorder, Neumora’s navacaprant ...
Neumora's KOASTAL-1 study results show navacaprant missed key goals in major depressive disorder. Additional studies and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback